Genomic scarring score predicts the response to PARP inhibitors in non-small cell lung cancer

Genomic scarring score predicts the response to PARP inhibitors in non-small cell lung cancer

Abstract PARP inhibitors (PARPi) have shown efficacy in tumours harbouring mutations in homologous recombination repair (HRR) genes. Somatic HRR mutations have been described in patients with Non-Small Cell Lung Cancer (NSCLC), but PARP inhibitors (PARPi) are not yet a therapeutic option. Here we as...

Full description

Saved in:
Bibliographic Details
Main Authors: Katerina Tsilingiri, Anna Chalari, Georgia Christopoulou, Alexandra Voutsina, Pantelis Constantoulakis, Κonstantinos Potaris, Ioannis Vamvakaris, Dora Hatzidaki, Georgina Zachou, Giannis Vatsellas, Vassilis Georgoulias, Athanasios Kotsakis, Apostolos Klinakis
Format: Article
Language:English
Published: Nature Portfolio 2024-12-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-024-00777-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41698-024-00777-6

Similar Items